Skip to main content

Bausch Health Companies Inc. reported a loss of $350 million in its latest quarter as its revenue moved lower.

The company formerly known as Valeant Pharmaceuticals says the loss for the quarter ended Sept. 30 amounted to $1.00 per diluted share.

The result compared with a profit of $1.30 billion or $3.69 per share in the same period a year earlier when it benefited from internal tax reorganization.

Revenue totalled nearly $2.14 billion for the quarter, down from nearly $2.22 billion a year ago.

On an adjusted basis, Bausch Health says it earned $403 million in its most recent quarter, up from $367 million in the third quarter of 2017.

The company says the increase was primarily due to lower interest costs and a lower tax rate.

Report an editorial error

Report a technical issue

Tickers mentioned in this story

Study and track financial data on any traded entity: click to open the full quote page. Data updated as of 28/03/24 4:00pm EDT.

SymbolName% changeLast
BHC-T
Bausch Health Companies Inc
+0.84%14.35

Follow related authors and topics

Authors and topics you follow will be added to your personal news feed in Following.

Interact with The Globe